Sevoflurane
| sevo | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 200.05 g/mol [1] |
| Appearance | Liquid [1] |
| Density | 1505 at 25 °C/D [1] |
| Melting point | < 25 °C [1] |
| Boiling point | 58.5 °C [1] |
| Solubility | Very slightly soluble [1] |
| Predicted LogP | 2.8 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C4H3F7O |
| IUPAC name | 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane |
| SMILES | C(OC(C(F)(F)F)C(F)(F)F)F |
| InChI | InChI=1S/C4H3F7O/c5-1-12-2(3(6,7)8)4(9,10)11/h2H,1H2 |
| InChIKey | DFEYYRMXOJXZRJ-UHFFFAOYSA-N |
| CAS number | 28523-86-6 |
| UNII | 38LVP0K73A |
| PubChem CID | 5206 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 15–23 hours |
| Metabolism | Liver by CYP2E1 |
| Excretion | Kidney |
| Routes of administration | Inhalation |
| Toxicity [] | |
|---|---|
| LD50 | Rat: - Rat) (A308) LC50: 49881 ppm/hr (Inhalation: 10.8 g/kg [1] |
Sevoflurane (also known as Sevofluran, Ultane, Sevorane, Sevoflurano, Sojourn, sevoflo, Sevofluranum, Mr6s4, Propane, 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)- or Sevocalm) is a substance of the ether class.
Chemistry
Stereochemistry []
Sevoflurane is achiral.
Druglikeness
Lipinski's rule of five
Sevoflurane matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- anesthetics (N01)
- anesthetics, general (N01A)
- halogenated hydrocarbons (N01AB)
- (N01AB08)
- sevoflurane (N01AB08)
MeSH Classification
Mechanism of action []
The precise mechanism of action of sevoflurane has not been fully elucidated. Like other halogenated inhalational anesthetics, sevoflurane induces anesthesia by binding to ligand-gated ion channels and blocking CNS neurotransmission. It has been suggested that inhaled anesthetics enhance inhibitory postsynaptic channel activity by binding GABA<sub>A</sub> and glycine receptors, and inhibit excitatory synaptic channel activity by binding nicotinic acetylcholine, serotonin, and glutamate receptors. Sevoflurane has an effect on several ionic currents, including the hyperpolarisation-activated cation current (I<sub>f</sub>), the T-type and L-type Ca<sup>2+</sup> currents (I<sub>Ca, T</sub> and I<sub>Ca, L</sub>), the slowly activating delayed rectifier K<sup>+</sup> currents (I<sub>Ks</sub>), and the Na<sup>+</sup>/Ca<sup>2+</sup> exchange current (I<sub>NCX</sub>). This ability to modulate ion channel activity can also regulate cardiac excitability and contractility. [1]
Medical side effects []
127 side effects listed on drug labels in SIDER 4.1 (sevoflurane).
- Mental disorder
- Anaphylactic shock
- Anaphylactoid reaction
- Bone disorder
- Bronchospasm
- Dermatitis contact
- Dyspnoea
- Oedema
- Dermatitis
- Rash
- Body temperature increased
- Gastrointestinal disorder
- Cardiac arrest
- Cardiac disorder
- Hepatitis
- Hyperkalaemia
- Hypersensitivity
- Immune system disorder
- Jaundice
- Renal failure acute
- Mediastinal disorder
- Muscle rigidity
- Nervous system disorder
- Pancreatitis
- Pruritus
- Renal failure
- Rhabdomyolysis
- Convulsion
- Torsade de pointes
- Tubulointerstitial nephritis
- Urethral disorder
- Urinary tract disorder
- Urticaria
- Ventricular fibrillation
- Ventricular tachycardia
- Wheezing
- Hepatic failure
- Hepatic function abnormal
- Swelling face
- Intracranial pressure increased
- Hepatic necrosis
- Electrocardiogram QT prolonged
- Eyelid oedema
- Malnutrition
- Skin disorder
- Muscle twitching
- Respiratory depression
- Pulmonary function test decreased
- Chest pain
- Chest discomfort
- Hepatobiliary disease
- Tonic clonic movements
- Acidosis
- Obstructive airways disorder
- Albuminuria
- Amblyopia
- Apnoea
- Arrhythmia
- Asthenia
- Atrial fibrillation
- Confusional state
- Feeling abnormal
- Conjunctivitis
- Cough
- Cough increased
- Dizziness
- Syncope
- Dysgeusia
- Fluorosis
- Glycosuria
- Headache
- Haemorrhage
- Haemoglobin
- Hiccups
- Hyperbilirubinaemia
- Hyperglycaemia
- Hypertension
- Hyperventilation
- Hypotension
- Body temperature decreased
- Hypothermia
- Laryngospasm
- Leukocytosis
- Hypertonia
- Nausea
- Nervousness
- Tension
- Oliguria
- Pain
- Pharyngitis
- Supraventricular extrasystoles
- Chills
- Salivary hypersecretion
- Stridor
- Shock
- Loss of consciousness
- Tachycardia
- Thrombocytopenia
- Angiopathy
- Vomiting
- Dry mouth
- Urinary retention
- Arrhythmia supraventricular
- Agitation
- Hypophosphataemia
- Atrioventricular block complete
- Ventricular extrasystoles
- Ventricular bigeminy
- Liver function test abnormal
- Dysuria
- Sputum increased
- Increased bronchial secretion
- Urine abnormality
- Urine analysis abnormal
- Breath holding
- Breath holding attack
- Hypoxia
- Hypoventilation
- Extrasystoles
- Atrioventricular block second degree
- Bradycardia
- Electrocardiogram ST segment depression
- Electrocardiogram T wave inversion
- Fluoride increased
- Insomnia
- Somnolence
- Respiratory failure
Indications
- Convulsion
Legal status []
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 5206, Sevoflurane. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5206
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Sevoflurane. UNII: 38LVP0K73A. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/38LVP0K73A
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 31 March 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Ultane- sevoflurane liquid. DailyMed. 18 August 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9aa6489-5a36-44ed-9512-b996833d82f7
Sojourn- sevoflurane liquid. DailyMed. 26 June 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fedfd1db-7e32-44b2-89e9-7bb00ee6810d
SevoFlo EPAR. European Medicines Agency. 14 August 2007. https://www.ema.europa.eu/en/medicines/veterinary/EPAR/sevoflo
SevoFlo PI. Union Register of medicinal products. 13 December 2002. https://ec.europa.eu/health/documents/community-register/html/v035.htm
Sevohale (previously known as Sevocalm) EPAR. European Medicines Agency. 29 July 2016. https://www.ema.europa.eu/en/medicines/veterinary/EPAR/sevohale-previously-known-sevocalm
Sevohale PI. Union Register of medicinal products. 24 June 2016. https://ec.europa.eu/health/documents/community-register/html/v196.htm
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 20:00:21 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 20:00:17 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 20:00:17 |
| gsrs | ok | 2026-11-20 20:00:17 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0015366) | 2026-11-20 20:00:17 |
| kegg | ok | 2026-11-20 20:00:19 |
| pubchem | ok | 2026-11-20 20:00:17 |
| missing (no r/tripreports posts mention it) | 2026-11-20 20:00:17 | |
| sider | ok | 2026-11-20 20:00:17 |
| structure | ok | 2026-11-20 20:00:17 |
| wikipedia | ok | 2026-11-20 20:00:17 |